Fig. 2.

Successful elimination of senescent cells in WBI-treated p16-3MR mice by GCV and ABT263. Panel a Flow cytometric detection of senescent RFP⁺ cells in single-cell suspensions obtained from the brains of control and WBI-treated p16-3MR mice that received vehicle, ganciclovir (GCV), or the senolytic drug ABT263. Dot plots of RFP-Booster Atto647N fluorescence (which correlates with p16-3MR expression) versus autofluorescence (583/26 nm) depict the percentage of senescent cells with bright fluorescence. Brains were analyzed 6 months post-WBI. Summary data are shown in panel b. Note that WBI significantly increases the presence of senescent cells in the mouse brain, which is reversed by both GCV and ABT263 treatment. Data are mean ± SEM (n = 4 for each data point). *P < 0.05 vs. control, ^#P < 0.05 vs. WBI. Panel c qPCR data showing expression of the senescence indicator p16-3MR component RFP in the cortices of control and WBI-treated p16-3MR mice that received vehicle, GCV, or ABT263. Data are mean ± SEM (n = 4–8 for each data point). *P < 0.05 vs. control, ^#P < 0.05 vs. WBI